Johnson & Johnson (J&J) has officially completed its acquisition of V-Wave, a company focused on innovative heart failure treatments. This acquisition enhances J&J’s MedTech division, which will now incorporate V-Wave’s Ventura interatrial shunt, a minimally invasive device designed to address heart failure.
The deal, initially announced in August 2024, is valued at up to $1.7 billion, with an upfront payment of $600 million. The acquisition aims to strengthen J&J’s position in the cardiovascular market and fulfill the urgent need for advanced therapies for heart failure.
Tim Schmid, the Worldwide Chairman of Johnson & Johnson MedTech, expressed enthusiasm about the integration of V-Wave into their operations. He highlighted the potential of the Ventura device to be the first of its kind on the market, promising significant benefits for patients with heart failure and reduced ejection fraction.
The Ventura device is designed to alleviate pressure on the left atrium and lungs in patients suffering from heart failure.
Although it has not yet received full approval from the U.S. Food and Drug Administration (FDA), it was granted breakthrough device designation in 2019.
J&J anticipates that the acquisition will lead to a dilution of adjusted earnings per share (EPS) by approximately $0.24 in 2024 and $0.06 in 2025. The company plans to provide an updated financial outlook during its third-quarter earnings report on October 15, 2024.
This acquisition aligns with J&J’s strategy to expand its portfolio in high-growth markets and deepen relationships with cardiologists specializing in structural interventions and heart failure treatments.
Related topics:
- Optimizing GDMT in Heart Failure Could Significantly Reduce Global Mortality Rates
- Staten Island Launches New Program to Combat Heart Disease
- New Study Highlights Potential for Finerenone in Treating Heart Failure